REPORTAGE – This disease, which leads to loss of vision, affects a quarter of people over 75 years old. Every day at the Quinze-Vingts hospital in Paris, 80 patients receive treatment directly injected into the eye to slow down its development.
A spring morning at the Quinze-Vingts National Hospital in Paris. The man who has been waiting for a few minutes in a small waiting room on the ground floor, in his sixties, seems stressed. Sitting on a seat, he twists his hands in all directions while looking worriedly at the door in front of him. This morning he is to receive his very first injection against age-related macular degeneration (AMD) which is attacking one of his eyes. The door suddenly opens on a nurse: “Come on, to us!».
Behind her, in what looks like a mini-operating room, a green-clad surgeon is preparing a syringe. For long minutes, the doctor and nurse carefully disinfect the patient’s previously anesthetized eye, before gently inserting the – very thin – needle into it. “It’s always impressive the first time, many patients fear having their eye gouged out. But in reality it is harmless and completely painless
This article is for subscribers only. You have 87% left to discover.
Pushing back the limits of science is also freedom.
Keep reading your article for €0.99 for the first month
Already subscribed? Login